[¹⁸F]-PSMA-1007-PET for evaluation of kidney function

Abstract

Purpose Prostate-specific membrane antigen (PSMA) is present in the proximal tubule cells of the kidneys. This results in high renal tracer uptake in PSMA-PET, which may contain useful information on renal function. As part of the evaluation for [¹⁷⁷Lu]-PSMA therapies, patients undergo PSMA-PET and additional [^99mTc]-mercapto-acetyltriglycine (MAG3) scintigraphy to assess renal function. Aim of this study was to evaluate estimation of renal function with [¹⁸F]-PSMA-1007-PET/CT (PSMA-PET) by comparison to timely MAG3-scintigraphies.

Materials and Methods We retrospectively investigated 73 prostate cancer patients with 93 timely available PSMA-PET/CT, MAG3-scintigraphies and serum creatinine. For determination of split renal function in PSMA-PET/CT, we evaluated the relative unilateral total renal PSMA uptake, i.e. SUV_mean multiplied by the renal volume (SRF_PSMA-TOTAL) and relative unilateral maximal standardized uptake value (SRF_SUV). These were compared to MAG3 split renal function (SRF_MAG3) using Pearson correlation and receiver operating characteristics analysis. For determination of global renal function, correlation of bilateral total renal PSMA uptake with MAG3 tubular excretion rate and serum creatinine was assessed.

Results SRF_MAG3 was strongly correlated with SRF_PSMA-TOTAL (r= 0.872, p<0.001) and with SRF_SUV (r=0.815, p<0.001). Relevant abnormalities of SRF_MAG3 (unilateral renal function < 25 %) could be detected with sensitivities and specificities of 90% and 92% for SRF_PSMA-TOTAL, and 80% and 95% for SRF_SUV. Measures of absolute renal function were only weakly correlated with bilateral total renal PSMA uptake.

Conclusion Renal [¹⁸F]-PSMA-1007 uptake allowed to quantify renal split function with good accuracy based on SRF_PSMA-TOTAL or SRF_SUV.

Keywords

PSMA - PET - kidney function - renal scintigraphy

• References

• 1 Rahbar K, Afshar-Oromieh A, Jadvar H. et al. PSMA Theranostics: Current Status and Future Directions. Mol Imaging 2018; 17: 1536012118776068
• 2 Backhaus P, Noto B, Avramovic N. et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018; 45 (05) 860-877
• 3 Silver DA, Pellicer I, Fair WR. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (01) 81-85
• 4 Delker A, Fendler WP, Kratochwil C. et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43 (01) 42-51
• 5 Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol 2016; 311 (01) F145-F161
• 6 Kratochwil C, Fendler WP, Eiber M. et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019; 46 (12) 2536-2544
• 7 Cozzi DA, Ceccanti S, Cozzi F. Non-invasive method for assessing split renal function. Minerva Urol Nefrol 2018; 70 (02) 230
• 8 Blaufox MD, De Palma D, Taylor A. et al. The SNMMI and EANM practice guideline for renal scintigraphy in adults. Eur J Nucl Med Mol Imaging 2018; 45 (12) 2218-2228
• 9 Rosar F, Pauly P, Ries M. et al. Determination of split renal function by PSMA imaging: comparison of 68Ga-PSMA-11 PET with 99mTc-MAG3 scintigraphy. Am J Nucl Med Mol Imaging 2020; 10 (05) 249-256
• 10 Valind K, Jögi J, Minarik D. et al. Dose-reduced [18F]PSMA-1007 PET is feasible for functional imaging of the renal cortex. EJNMMI Phys 2021; 8 (01) 70
• 11 Cardinale J, Martin R, Remde Y. et al. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals (Basel) 2017; 10 (04) 77
• 12 Al-Adra DP, Lambadaris M, Barbas A. et al. Donor kidney volume measured by computed tomography is a strong predictor of recipient eGFR in living donor kidney transplantation. World J Urol 2019; 37 (09) 1965-1972
• 13 Janki S, Kimenai HJAN, Dijkshoorn ML. et al. Validation of Ultrasonographic Kidney Volume Measurements: A Reliable Imaging Modality. Exp Clin Transplant 2018; 16 (01) 16-22
• 14 Coruh AG, Uzun C, Akkaya Z. et al. Is There a Correlation with Pre-donation Kidney Volume and Renal Function in the Renal Transplant Recipient?: A Volumetric Computed Tomography Study. Transplant Proc 2019; 51 (07) 2312-2317
• 15 Werner E, Blasl C, Reiners C. Reproducibility of technetium-99m-MAG3 clearance using the Bubeck method. J Nucl Med 1998; 39 (06) 1066-1069
• 16 Yamazaki T, Maruoka S, Sakamoto K. Quantification of renal function with 99mTc-MAG3--quantification of tubular extraction rate using Bubeck’s method. Kaku Igaku 1995; 32 (11) 1199-1206
• 17 Piepsz A, Tondeur M, Ham H. Relative 99mTc-MAG3 renal uptake: reproducibility and accuracy. J Nucl Med 1999; 40: 972-976
• 18 Gafita A, Wang H, Robertson A. et al. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?. J Nucl Med 2022; 63 (02) 226-232
• 19 Werner RA, Pomper MG, Buck AK. et al. SPECT and PET Radiotracers in Renal Imaging. Semin Nucl Med 2022; 52 (04) 406-418
• 20 Blaufox MD, De Palma D, Taylor A. et al. The SNMMI and EANM practice guideline for renal scintigraphy in adults. Eur J Nucl Med Mol Imaging 2018; 45 (12) 2218-2228
• 21 Zajic T, Moser E. Verfahrensanweisung zur dynamischen Nierenfunktionsszintigraphie [Procedure guidelines for dynamic renal scintigraphy]. Nuklearmedizin 2004; 43 (05) 177-180
• 22 Schicha H, Schober O. Nuklearmedizin – Basiswissen und klinische Anwendung 6. Auflage. In: . 2007: 220-226
• 23 Rassek P, Schäfers M, Rahbar K. et al. [18F]-PSMA-1007-PET for evaluation of kidney function, 25 October 2022, PREPRINT (Version 1) available at Research Square.